Search

Displaying results 1501 - 1510 of 10000 in total
  1. Drug

    Streptozocin

    go.drugbank.com/drugs/DB00428
    ApprovedInvestigational

    An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.

    Synonyms: N-D-Glucosyl-(2)-N'-nitrosomethylurea, N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff
  2. Drug

    Ramipril

    go.drugbank.com/drugs/DB00178
    ApprovedInvestigational

    Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular

    Mixtures: RAMIPRIL COMP HEU 5/25MG N
  3. Drug

    Samidorphan

    go.drugbank.com/drugs/DB12543
    ApprovedInvestigational

    by Alkermes Inc. … [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™

  4. Drug

    Glycol salicylate

    go.drugbank.com/drugs/DB11323
    Approved

    Glycol salicylate (GS), composed of salicylic acid (SA) and ethylene glycol, is a non-steroidal anti-inflammatory drug [L2687].

    Mixtures: New Ammeltz, NEW AMMELTZ YOKO YOKOCategories: Anti-Inflammatory Agents, Non-Steroidal
  5. Drug

    R673

    go.drugbank.com/drugs/DB05466
    Experimental

    The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning … R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability and shows low P450-based drug interaction potential.

  6. Target

    Tyrosine-protein phosphatase non-receptor type 4

    go.drugbank.com/bio_entities/BE0000980
    TargetHumans

    Phosphatase that plays a role in immunity, learning, synaptic plasticity or cell homeostasis (PubMed:25825441, PubMed:27246854). Regulates neuronal cell homeostasis by protecting neurons against apoptosis (PubMed:20086240). Negatively re...

    Polypeptides: Tyrosine-protein phosphatase non-receptor type 4
  7. Target

    Non-selective voltage-gated ion channel VDAC2

    go.drugbank.com/bio_entities/BE0002469
    TargetHumans

    Non-selective voltage-gated ion channel that mediates the transport of anions and cations through the mitochondrion outer membrane and plasma membrane (PubMed:8420959).

    Polypeptides: Non-selective voltage-gated ion channel VDAC2
  8. Target

    Tyrosine-protein phosphatase non-receptor type 6

    go.drugbank.com/bio_entities/BE0009941
    TargetHumans

    Tyrosine phosphatase enzyme that plays important roles in controlling immune signaling pathways and fundamental physiological processes such as hematopoiesis (PubMed:14739280, PubMed:29925997). Dephosphorylates and negatively regulate se...

    Polypeptides: Tyrosine-protein phosphatase non-receptor type 6
  9. Drug

    Bretylium

    go.drugbank.com/drugs/DB01158
    Approved

    Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.

    Synonyms: 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium, N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium
  10. Drug

    Roxadustat

    go.drugbank.com/drugs/DB04847
    ApprovedInvestigational

    It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels. … [A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323]